Prevention of liver cancer

Current Oncology Reports

Volumn 4, Issue 6, 2002, Pages 464-470

  Guyton, Kathryn Z ^a   Kensler, Thomas W ^a  

^a The Johns Hopkins University   (United States)

Author keywords

Acyclic Retinoid; Aflatoxin; Ebselen; Glycyrrhizin; Oltipraz

Indexed keywords

ANTIVIRUS AGENT; CARCINOGEN;

ANIMAL; CHEMOPROPHYLAXIS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTIVIRAL AGENTS; CARCINOGENS, ENVIRONMENTAL; CARCINOMA, HEPATOCELLULAR; CHEMOPREVENTION; GENES, P53; HUMANS; LIVER NEOPLASMS; RISK FACTORS;

EID: 0036834810     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-002-0057-4     Document Type: Article

References (68)

1. Teo EK, Fock KM: Hepatocellular carcinoma: an Asian perspective. Dig Dis 2001, 19:263–268.
2. Koda M, Murawaki Y, Mitsuda A, et al.: Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma. Cancer 2000, 88:529–537.
3. Bilimoria MM, Lauwers GY, Doherty DA, et al.: Underlying liver disease, not tumor factors, predicts long-term survival after resection of hepatocellular carcinoma. Arch Surg 2001, 136:528–535.
4. Evans AA, Chen G, Ross EA, et al.: Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiol Biomarkers Prev 2002, 11:369–376. This prospective cohort study of 58,545 men and 25,340 women identified HBV infection as the primary risk factor for HCC mortality in this Haimen City, China cohort.
5. Yoshizawa H: Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002, 62(suppl 1):8–17.
6. Mori M, Hara M, Wada I, et al.: Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000, 151:131–139.
7. Hellerbrand C, Hartmann A, Richter G, et al.: Hepatocellular carcinoma in southern Germany: epidemiological and clinicopathological characteristics and risk factors. Dig Dis 2001, 19:345–351.
8. Monto A, Wright TL: The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol 2001, 28:441–449.
9. Kao JH, Chen DS: Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma. Int J Cancer 2002, 97:269–271.
10. Prince AM, Shata MT: Immunoprophylaxis of hepatitis C virus infection. Clin Liver Dis 2001, 5:1091–1103.
11. Kao JH, Hsu HM, Shau WY, et al.: Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001, 139:349–352.
12. Chang MH, Shau WY, Chen CJ, et al.: Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA 2000, 284:3040–3042.
13. Leung NW, Lai CL, Chang TT, et al.: Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527–1532.
14. Kazim SN, Wakil SM, Khan LA, et al.: Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002, 359:1488–1489.
15. Cheng YC: Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers. Cancer Lett 2001, 162(suppl):S33-S37.
16. Le Guerhier F, Pichoud C, Jamard C, et al.: Antiviral activity of beta-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother 2001, 45:1065–1077.
17. Nishiguchi S, Shiomi S, Nakatani S, et al.: Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001, 357:196–197. This prospective, randomized, controlled study of 90 chronic HCV patients found a protective effect of interferon α on HCC development and death (risk ratios vs symptomatic treatment, 0.256 and 0.135, respectively) after 8.7 years of follow-up.
18. Ikeda K, Saitoh S, Kobayashi M, et al.: Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastroenterol Hepatol 2001, 16:406–415.
19. Toyoda H, Kumada T, Nakano S, et al.: Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C. Oncology 2001, 61:134–142.
20. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ: Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001, 15:689–698. This high-quality meta-analysis, which considered 11 studies with 2178 HCV patients, found a significant protective effect of interferon α on HCC development. Although the effect was most pronounced for sustained responders, a reduced HCC incidence in nonresponders was also found.
21. Takimoto M, Ohkoshi S, Ichida T, et al.: Interferon inhibits progression of liver fibrosis and reduces the risk of hepatocarcinogenesis in patients with chronic hepatitis C: a retrospective multicenter analysis of 652 patients. Dig Dis Sci 2002, 47:170–176.
22. Camma C, Giunta M, Andreone P, Craxi A: Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001, 34:593–602. This excellent meta-analysis considered three randomized and 15 nonrandomized controlled trials including 4614 patients and comparing interferon α treatment with no treatment. A protective effect of interferon α in HCV was identified, but the magnitude was low and related to response to interferon α. Interferon α did not affect HCC development in HBV-related cirrhosis.
23. Yuen MF, Hui CK, Cheng CC, et al.: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001, 34:139–145.
24. Kumada H: Long-term treatment of chronic hepatitis C with glycyrrhizin (stronger neo-minophagen C [SNMC]) for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002, 62(suppl 1):94–100.
25. The Ginseng-HCC Chemopreventive Study Osaka Group: Study on chemoprevention of hepatocellular carcinoma by ginseng: an introduction to the protocol. J Korean Med Sci 2001, 16(suppl):S70-S74.
26. Cyong JC, Ki SM, Iijima K, et al.: Clinical and pharmacological studies on liver diseases treated with Kampo herbal medicine. Am J Chin Med 2000, 28:351–360.
27. Okuno M, Kojima S, Moriwaki H: Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol 2001, 16:1329–1335.
28. Sofowora GG, Choo EF, Mayo G, et al.: In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother Pharmacol 2001, 47:505–510.
29. Dick RA, Kwak MK, Sutter TR, Kensler TW: Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase: a new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase. J Biol Chem 2001, 276:40803–40810. This study demonstrated a novel catalytic activity of NAD(P)H-dependent alkenal/one oxidoreductase (leukotriene B412-hydroxydehydrogenase): reduction of the α,β-carbon=carbon double bond of α,β-unsaturated aldehydes and ketones such as 4-hydroxy-2-nonenal. In addition, forced overexpression of the enzyme protected cells from the toxicity of 4-hydroxy-2-nonenal, a major product of lipid peroxidation.
30. Kwak MK, Itoh K, Yamamoto M, et al.: Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med 2001, 7:135–145. This investigation characterized the expression patterns of over a dozen genes inducible by 3H-1,2-dithiole-3-thione in both wild-type and nrf2-disrupted mice. Nrf2 was found to play a central regulatory role in the constitutive and dithiolthione-inducible expression of multiple phase 2 and antioxidative enzymes.
31. Egner PA, Wang JB, Zhu YR, et al.: Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci U S A 2001, 98:14601–14606. This double-blind, placebo-controlled study of chlorophyllin (100 mg three times a day for 4 months) in 180 residents of Qidong, People’s Republic of China, demonstrated a 55% reduction in urinary aflatoxin-DNA adducts (P=0.036).
32. Walton M, Egner P, Scholl PF, et al.: Liquid chromatography electrospray-mass spectrometry of urinary aflatoxin biomarkers: characterization and application to dosimetry and chemoprevention in rats. Chem Res Toxicol 2001, 14:919–926.
33. Fukushima S, Takada N, Wanibuchi H, et al.: Suppression of chemical carcinogenesis by water-soluble organosulfur compounds. J Nutr 2001, 131:1049S-1053S.
34. Yang CF, Liu J, Wasser S, et al.: Inhibition of ebselen on aflatoxin B(1)-induced hepatocarcinogenesis in Fischer 344 rats. Carcinogenesis 2000, 21:2237–2243.
35. Watanabe T, Sugie S, Okamoto K, et al.: Chemopreventive effects of scordinin on diethylnitrosamine and phenobarbital-induced hepatocarcinogenesis in male F344 rats. Jpn J Cancer Res 2001, 92:603–609.
36. Rajeshkumar NV, Kuttan R: Inhibition of N-nitrosodiethylamine-induced hepatocarcinogenesis by Picroliv. J Exp Clin Cancer Res 2000, 19:459–465.
37. Ahmed S, Rahman A, Mathur M, et al.: Anti-tumor promoting activity of Asteracantha longifolia against experimental hepatocarcinogenesis in rats. Food Chem Toxicol 2001, 39:19–28.
38. Liu J, Yang CF, Wasser S, et al.: Protection of salvia miltiorrhiza against aflatoxin-B1-induced hepatocarcinogenesis in Fischer 344 rats dual mechanisms involved. Life Sci 2001, 69:309–326.
39. Maruyama S, Nagasue N, Dhar DK, et al.: Preventive effect of FK143, a 5alpha-reductase inhibitor, on chemical hepatocarcinogenesis in rats. Clin Cancer Res 2001, 7:2096–2104.
40. Qin G, Ning Y, Lotlikar PD: Chemoprevention of aflatoxin B1-initiated and carbon tetrachloride-promoted hepatocarcinogenesis in the rat by green tea. Nutr Cancer 2000, 38:215–222.
41. Hosaka S, Kawa S, Aoki Y, et al.: Hepatocarcinogenesis inhibition by caffeine in ACI rats treated with 2-acetylaminofluorene. Food Chem Toxicol 2001, 39:557–561.
42. Kaji I, Tatsuta M, Iishi H, et al.: Inhibition by d-limonene of experimental hepatocarcinogenesis in Sprague-Dawley rats does not involve p21(ras) plasma membrane association. Int J Cancer 2001, 93:441–444.
43. Kakizaki S, Takagi H, Fukusato T, et al.: Effect of alphatocopherol on hepatocarcinogenesis in transforming growth factor-alpha (TGF-alpha) transgenic mice treated with diethylnitrosamine. Int J Vitam Nutr Res 2001, 71:261–267.
44. Basak R, Bhattacharya R, Chatterjee M: 1 alpha,25-Dihydroxyvitamin D(3) inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem 2001, 81:357–367.
45. Silveira ER, Naves MM, Vannucchi H, et al.: Vitamin A and alltrans and 9-cis retinoic acids inhibit cell proliferation during the progression phase of hepatocarcinogenesis in Wistar rats. Nutr Cancer 2001, 39:244–251.
46. Jackson PE, Qian GS, Friesen MD, et al.: Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res 2001, 61:33–35.
47. Tannapfel A, Busse C, Weinans L, et al.: INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001, 20:7104–7109.
48. Azechi H, Nishida N, Fukuda Y, et al.: Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology 2001, 60:346–354.
49. Kaneto H, Sasaki S, Yamamoto H, et al.: Detection of hypermethylation of the p16(INK4A) gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut 2001, 48:372–377.
50. Bugni JM, Poole TM, Drinkwater NR: The little mutation suppresses DEN-induced hepatocarcinogenesis in mice and abrogates genetic and hormonal modulation of susceptibility. Carcinogenesis 2001, 22:1853–1862.
51. Klocke R, Bartels T, Jennings G, et al.: Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c-myc in the liver. FASEB J 2001, 15:1404–1406.
52. Kwun HJ, Jung EY, Ahn JY, et al.: p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol 2001, 82:2235–2241.
53. Hatanaka Y, Nakae D, Mutai M, et al.: Decreased expression of Bcl-x protein during hepatocarcinogenesis induced exogenously and endogenously in rats. Jpn J Cancer Res 2001, 92:1270–1277.
54. Baba M, Iishi H, Tatsuta M: Transfer of bcl-xs plasmid is effective in preventing and inhibiting rat hepatocellular carcinoma induced by N-nitrosomorpholine. Gene Ther 2001, 8:1149–1156.
55. Vogel A, Kneip S, Barut A, et al.: Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 2001, 121:1136–1144. This German case-control study involved 59 cancer patients and 70 control subjects. The uridine 5′-diphosphate-glucuronosyltransferase allele UGT1A7*3, which encodes a protein with low carcinogen detoxification activity, was significantly associated with HCC.
56. Sun CA, Wang LY, Chen CJ, et al.: Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001, 22:1289–1294. This Taiwanese case-control study of chronic HBV carriers involved 79 HCC patients and 149 control subjects. A statistically significant correlation between HCC risk and serum AFB1-albumin adducts was found. In addition, the effect of aflatoxin exposure on HCC risk was more pronounced among HBV carriers with the GSTT1 null genotype (P=0.03).
57. Schwarz KB, Kew M, Klein A, et al.: Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. Dig Dis Sci 2001, 46:2173–2178.
58. Kitada T, Seki S, Iwai S, et al.: In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol 2001, 35:613–618.
59. Moriya K, Nakagawa K, Santa T, et al.: Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001, 61:4365–4370.
60. Zhou ZQ, Manguino D, Kewitt K, et al.: Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6-methylguanine-DNA methyltransferase. Proc Natl Acad Sci U S A 2001, 98:12566–12571.
61. Walter CA, Zhou ZQ, Manguino D, et al.: Health span and life span in transgenic mice with modulated DNA repair. Ann NY Acad Sci 2001, 928:132–140.
62. Takahashi Y, Nakatsuru Y, Zhang S, et al.: Enhanced spontaneous and aflatoxin-induced liver tumorigenesis in xeroderma pigmentosum group A gene-deficient mice. Carcinogenesis 2002, 23:627–633.
63. Matsushima-Nishiwaki R, Okuno M, Adachi S, et al.: Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res 2001, 61:7675–7682. In surgically resected HCC and in HuH17 human HCC-derived cells, RXR-α was phosphorylated at serine 260 by MAPK. Phosphorylated RXR-α lost its transactivation activity, was resistant to degradation, and was associated with increased proliferation.
64. Okuno M, Sano T, Matsushima-Nishiwaki R, et al.: Apoptosis induction by acyclic retinoid: a molecular basis of ‘clonal deletion’ therapy for hepatocellular carcinoma. Jpn J Clin Oncol 2001, 31:359–362.
65. Feng DY, Zheng H, Tan Y, Cheng RX: Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 2001, 7:33–36.
66. Tarn C, Lee S, Hu Y, et al.: Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001, 276:34671–34680.
67. Lara-Pezzi E, Roche S, Andrisani OM, et al.: The hepatitis B virus HBx protein induces adherens junction disruption in a src-dependent manner. Oncogene 2001, 20:3323–3331.
68. Tu H, Bonura C, Giannini C, et al.: Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001, 61:7803–7810.